Comparison of ice fog methods and monitoring of controlled nucleation success after freeze-drying.

Batch homogeneity Controlled nucleation Freeze-drying Nucleation temperature Product properties

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
10 Mar 2019
Historique:
received: 14 08 2018
revised: 19 11 2018
accepted: 13 12 2018
pubmed: 1 1 2019
medline: 14 6 2019
entrez: 1 1 2019
Statut: ppublish

Résumé

Improving freeze-drying processes regarding drying time and batch homogeneity is subject of ongoing research work. In this context, controlled nucleation raised great expectations. However, practically we face some challenges, e.g. how to non-destructively monitor successfully performed controlled nucleation. The question if different controlled nucleation methods lead to comparable products, as not every method can easily be implemented in lab and production scale equipment, is also of high interest. Additionally, the optimal nucleation temperature for controlled nucleation is an open question. In our study, we addressed these challenges. We successfully evaluated frequency modulated spectroscopy as a fast and non-destructive method to monitor controlled nucleation success and batch homogeneity. We found that the better homogeneity generated by controlled nucleation during the freezing step did not sustain in the dried product. Lyophilizates produced by three different ice fog methods for controlled nucleation were characterized by comparable specific surface areas but differed in residual moisture content. To investigate the impact of the ice nucleation temperature (T

Identifiants

pubmed: 30597272
pii: S0378-5173(18)30974-8
doi: 10.1016/j.ijpharm.2018.12.056
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Ice 0
Immunoglobulin G 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

18-28

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Ilona Vollrath (I)

Coriolis Pharma Research GmbH, D-82152 Martinsried, Germany; Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University, D-81377 Munich, Germany.

Wolfgang Friess (W)

Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University, D-81377 Munich, Germany.

Angelika Freitag (A)

Coriolis Pharma Research GmbH, D-82152 Martinsried, Germany.

Andrea Hawe (A)

Coriolis Pharma Research GmbH, D-82152 Martinsried, Germany. Electronic address: andrea.hawe@coriolis-pharma.com.

Gerhard Winter (G)

Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University, D-81377 Munich, Germany.

Articles similaires

Humans COVID-19 Immunoglobulin G Antibodies, Viral SARS-CoV-2
Humans Amyotrophic Lateral Sclerosis Male Middle Aged Female
Humans Malaria, Vivax Plasmodium vivax Antibodies, Protozoan Adult

Classifications MeSH